Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model

International Journal of Molecular Medicine

Volumn 19, Issue 1, 2007, Pages 75-79

  Ideno, Junichi ^a   Mizukami, Hiroaki ^a   Kakehashi, Akihiro ^a   Saito, Yuka ^a   Okada, Takashi ^a   Urabe, Masashi ^a   Kume, Akihiro ^a   Kuroki, Masatoshi ^a   Kawakami, Masanobu ^a   Ishibashi, Shun ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adeno associated viral vector; Diabetic retinopathy; Gene therapy; Sflt 1; Spontaneously diabetic non obese Torii rat

Indexed keywords

FLT1 PROTEIN, RAT; VASCULOTROPIN RECEPTOR 1;

ANIMAL; AQUEOUS HUMOR; ARTICLE; CHEMISTRY; DIABETIC RETINOPATHY; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; METHODOLOGY; RAT; RETINA;

ANIMALS; AQUEOUS HUMOR; BLOOD GLUCOSE; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; MALE; RATS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34447253623     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.1.75     Document Type: Article

References (45)

1. Hyman L: Epidemiology of eye disease in the elderly. Eye 1: 330-341, 1987.
2. Klein BE and Klein R: Ocular problems in older Americans with diabetes. Clin Geriatr Med 6: 827-837, 1990.
3. King H and Rewers M: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 16: 157-177, 1993.
4. Hotta N, Nakamura J, Sakakibara F, et al: Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant. Am J Physiol 273: E965-E971, 1997.
5. Robison WG Jr, Nagata M, Tillis TN, Laver N and Kinoshita JH: Aldose reductase and pericyte-endothelial cell contacts in retina and optic nerve. Invest Ophthalmol Vis Sci 30: 2293-2299, 1989. (Pubitemid 20004227)
6. Aiello LP, Bursell SE, Clermont A, et al: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46: 1473-1480, 1997.
7. Lee TS, MacGregor LC, Fluharty SJ and King GL: Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 83: 90-94, 1989.
8. Nakamura J, Kato K, Hamada Y, et al: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48: 2090-2095, 1999.
9. Hammes HP, Wellensiek B, Kloting I, Sickel E, Bretzel RG and Brownlee M: The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 41: 165-170, 1998. (Pubitemid 28088392)
10. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K and Horiuchi S: The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40: 764-769, 1997. (Pubitemid 27306953)
11. Aiello LP: Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29: 354-362, 1997.
12. Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487, 1994.
13. Ozaki H, Seo MS, Ozaki K, et al: Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156: 697-707, 2000. (Pubitemid 30643824)
14. Ferrara N, Houck K, Jakeman L and Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32, 1992.
15. Jakeman LB, Winer J, Bennett GL, Altar CA and Ferrara N: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89: 244-253, 1992.
16. Senger DR, Perruzzi CA, Feder J and Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629-5632, 1986. (Pubitemid 17177959)
17. Thieme H, Aiello LP, Takagi H, Ferrara N and King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 44: 98-103, 1995.
18. Adamis AP, Miller JW, Bernal MT, et al: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450, 1994. (Pubitemid 24307211)
19. Boulton M, Gregor Z, McLeod D, et al: Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 81: 228-233, 1997. (Pubitemid 27120890)
20. Okamoto N, Tobe T, Hackett SF, et al: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151: 281-291, 1997.
21. Adamis AP, Shima DT, Tolentino MJ, et al: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114: 66-71, 1996. (Pubitemid 26026196)
22. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R and Smith LE: Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93: 4851-4856, 1996. (Pubitemid 26162840)
23. Aiello LP, Pierce EA, Foley ED, et al: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457-10461, 1995.
24. Goldman CK, Kendall RL, Cabrera G, et al: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95: 8795-8800, 1998.
25. Hasumi Y, Mizukami H, Urabe M, et al: Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 62: 2019-2023, 2002. (Pubitemid 34408446)
26. Kendall RL and Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993.
27. Kong HL, Hecht D, Song W, et al: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9: 823-833, 1998.
28. Shiose S, Sakamoto T, Yoshikawa H, et al: Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci 41: 2395-2403, 2000. (Pubitemid 30624362)
29. Kendall RL, Wang G and Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996.
30. Bainbridge JW, Mistry A, De Alwis M, et al: Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 9: 320-326, 2002. (Pubitemid 34285145)
31. Honda M, Sakamoto T, Ishibashi T, Inomata H and Ueno H: Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7: 978-985, 2000. (Pubitemid 30386663)
32. Shinohara M, Masuyama T, Shoda T, et al: A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 1: 89-100, 2000.
33. Kakehashi A, Saito Y, Mori K, et al: Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev (Epub ahead of print March 30, 2006).
34. Dudus L, Anand V, Acland GM, et al: Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 39: 2545-2553, 1999. (Pubitemid 29197300)
35. Martin KR, Klein RL and Quigley HA: Gene delivery to the eye using adeno-associated viral vectors. Methods 28: 267-275, 2002. (Pubitemid 35341091)
36. Auricchio A, Behling KC, Maguire AM, et al: Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 6: 490-494, 2002. (Pubitemid 35214870)
37. Lotery AJ, Yang GS, Mullins RF, et al: Adeno-associated virus type 5: transduction efficiency and cell-type specificity in the primate retina. Hum Gene Ther 14: 1663-1671, 2003.
38. Rabinowitz JE, Rolling F, Li C, et al: Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801, 2002. (Pubitemid 34033377)
39. Yang GS, Schmidt M, Yan Z, et al: Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol 76: 7651-7660, 2002. (Pubitemid 34760989)
40. Yoshimura I, Mizuguchi Y, Miyajima A, Asano T, Tadakuma T and Hayakawa M: Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol 171: 2467-2470, 2004. (Pubitemid 38625516)
41. Zhang M, Volpert O, Shi YH and Bouck N: Maspin is an angiogenesis inhibitor. Nat Med 6: 196-199, 2000.
42. Hermens WT, ter Brake O, Dijkhuizen PA, et al: Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 10: 1885-1891, 1999.
43. Zolotukhin S, Byrne BJ, Mason E, et al: Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985, 1999. (Pubitemid 29295202)
44. Kadof PF, Takahashi Y, Wyman M, Ferris F III: Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 113: 352-354, 1995.
45. Casey R and Li WW: Factors controlling ocular angiogenesis. Am J Ophthalmol 124: 521-529, 1997.